MedTrace Logo

Use of Baricitenib to Maintain of Remission

NCT05686746 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-01-17

No results posted yet for this study

Summary

Baricitinib a selective Janus kinase (JAK) inhibitors 1\&2 have been recognized as a potential therapeutic option in systemic lupus (SLE), also known Baricitinib, a JAK inhibitor, has demonstrated efficacy and safety in the treatment of dermatitis and arthritis 1 ; however, no JAK inhibitor studies have been conducted in lupus nephritis (LN) maintain remission to date.

Conditions

  • Lupus or SLE
  • Nephritis

Interventions

DRUG

Baricitinib 4 MG

4 mg oral daily

DRUG

Baricitinib 2 MG

2 mg oral daily

DRUG

MMF

1000 mg oral daily

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Manal Hassanien, MD · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-06-01
Completion
2023-08-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05686746 on ClinicalTrials.gov